Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Despite modern biologic therapies, Crohn's disease (CD) continues to be linked to significantly higher mortality risk compared to matched controls — while ulcerative colitis (UC) mortality remains on par. A large population-based study found CD patients in the biologic era die younger and face elevated risks from renal disease, colon cancer, and sepsis. The findings call for sustained long-term monitoring in high-risk CD populations.
Even as biologic therapies have transformed inflammatory bowel disease (IBD) treatment, a new population-based study finds that Crohn's disease (CD) still carries a meaningfully higher risk of death compared to the general population — while ulcerative colitis (UC) does not. The study, published in the Journal of Crohn's and Colitis, tracked over 13,000 IBD patients matched with roughly 133,000 non-IBD controls through 2023.
In the biologic era, CD patients had a 34% higher mortality risk than controls and died at a younger median age (73 vs. 76 years). Women with CD faced particularly elevated risk, regardless of biologic use. UC patients, by contrast, showed mortality rates comparable to controls.
By the Numbers:
Why it matters: Biologics haven't fully closed the mortality gap for CD patients. Clinicians need to maintain vigilant long-term monitoring for comorbidities — especially renal disease, cancer, and infection — in this high-risk population.
